Prostate Cancer, Hereditary, 4 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HPC4 MCID: PRS135 MIFTS: 22	Prostate Cancer, Hereditary, 4 (HPC4) Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Prostate Cancer, Hereditary, 4

MalaCards integrated aliases for Prostate Cancer, Hereditary, 4:

Name: Prostate Cancer, Hereditary, 4 ⁵⁶ ¹³ ⁷¹

Prostate Cancer, Hereditary, on Chromosome 7 ⁵⁶

Prostate Cancer, Susceptibility to, 4 ⁵⁶

Prostate Cancer 4 ⁵⁶

Hpc4 ⁵⁶

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁶ 608658

MedGen ⁴¹ C1837593

UMLS ⁷¹ C1837593

Sources

Summaries for Prostate Cancer, Hereditary, 4

MalaCards based summary : Prostate Cancer, Hereditary, 4, also known as prostate cancer, hereditary, on chromosome 7, is related to prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 4 is HPC4 (Prostate Cancer, Hereditary, 4). The drugs 4-Aminopyridine and Potassium Channel Blockers have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and lung.

Wikipedia : ⁷⁴ Prostate cancer, hereditary, 4 is a protein that in humans is encoded by the HPC4... more...

More information from OMIM: 608658

Sources

Related Diseases for Prostate Cancer, Hereditary, 4

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1	Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3	Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5	Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7	Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10	Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13	Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14	Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2	Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 4 via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	prostate cancer	11.5

Sources

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 4

Clinical features from OMIM:

608658

Sources

Drugs & Therapeutics for Prostate Cancer, Hereditary, 4

Drugs for Prostate Cancer, Hereditary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 7)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

4-Aminopyridine

Approved

Phase 4

504-24-5

1727

Synonyms:

.gamma.-Aminopyridine

[J.Pharmacol.Exp.Ther. 275:864 (1995)]

275875_ALDRICH

36687_FLUKA

36687_RIEDEL

4 Aminopyridine

4 Aminopyridine Sustained Release

4 AP

4-aminopyridine

4-Aminopyridine

4-Aminopyridine 10

4-Aminopyridine Sustained Release

4-AP

4-Pyridinamine

4-Pyridylamine

504-24-5

5-22-09-00106 (Beilstein Handbook Reference)

A 0152

A0414

A78403_ALDRICH

AB1004971

AC1L1C3R

AC1Q52BM

AC-907/25014071

AI3-52547

AKOS000119896

Amaya

Amino-4 pyridine

Amino-4-Pyridine

Ampydin

Ampyra

Avitrol

Avitrol 200

BB_SC-6974

Bio1_000353

Bio1_000842

Bio1_001331

Bio2_000282

Bio2_000762

BRN 0105782

BSPBio_001562

C13728

C5H6N2

Caswell No. 038

CHEBI:34385

CHEMBL284348

CID1727

Compound 1861

D015761

D04127

Dalfampridine

DivK1c_000572

EINECS 207-987-9

EL-970

EPA Pesticide Chemical Code 069201

EU-0100032

Fampridina

Fampridine

Fampridine (USAN/INN)

Fampridine [USAN:INN]

Fampridine SR

Fampridine-PR

Fampridine-SR

Fampridinum

FT-0083754

gamma-Aminopyridine

HC150041

HMS1361O04

HMS1791O04

HMS1921H15

HMS1989O04

HMS2092F05

HMS501M14

HSDB 6037

IDI1_000572

IDI1_034032

InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7

KBio1_000572

KBio2_000282

KBio2_000635

KBio2_002850

KBio2_003203

KBio2_005418

KBio2_005771

KBio3_000563

KBio3_000564

KBio3_001888

KBioGR_000282

KBioGR_001505

KBioSS_000282

KBioSS_000635

Lopac0_000032

Lopac-A-0152

LS-130202

Mi-W-3

MLS000069400

MolPort-000-146-022

NCGC00015009-01

NCGC00015009-03

NCGC00015009-12

NCGC00024890-01

NCGC00024890-02

NCGC00024890-03

NCGC00024890-04

NCGC00024890-05

NCGC00024890-06

NCGC00024890-07

NCGC00024890-08

NCGC00024890-09

NCGC00024890-10

nchem.892-comp4

Neurelan

Neurelan (TN)

NINDS_000572

NSC 15041

NSC15041

p-Aminopyridine

p-Aminopyridine [UN2671] [Poison]

Philips 1861

Phillips 1861

Pimadin (free base)

Prc 1237

Pymadin

Pymadine

pyridin-4-amine

pyridin-4-ylamine

PYRIDINE,4-AMINO

RCRA waste no. P008

SDCCGMLS-0066228.P001

SMR000058211

SPBio_001486

Spectrum_000155

SPECTRUM1501130

Spectrum2_001413

Spectrum3_000914

Spectrum4_001013

Spectrum5_001501

STK298717

Sustained Release, 4-Aminopyridine

TL8003344

Tocris-0940

UNII-BH3B64OKL9

UPCMLD-DP125

UPCMLD-DP125:001

VMI 103

VMI 10-3

VMI103

VMI-103

VMI-10-3

WLN: T6NJ DZ

γ-Aminopyridine

Potassium Channel Blockers

Phase 4

Choline

Approved, Nutraceutical

Phase 3

62-49-7

305

Synonyms:

(2-Hydroxyethyl)trimethyl ammonium

(2-Hydroxyethyl)trimethylammonium

(beta-Hydroxyethyl)trimethylammonium

2-Hydroxy-N,N,N-trimethylethanaminium

2-Hydroxy-N,N,N-trimethyl-ethanaminium

Bilineurine

Biocolina

Biocoline

Bitartrate, choline

Bursine

Chloride, choline

Choline bitartrate

Choline cation

Choline chloride

Choline citrate

Choline hydroxide

Choline ion

CHOLINE ion

Choline O sulfate

Choline O-sulfate

Cholinum

Citrate, choline

Fagine

Hepacholine

Hormocline

Hydroxide, choline

Lipotril

N,N,N-trimethylethanol-ammonium

N,N,N-Trimethylethanolammonium

N,N,N-Trimethylethanol-ammonium

Neocolina

N-trimethylethanolamine

N-Trimethylethanolamine

O-Sulfate, choline

Paresan

trimethylethanolamine

Trimethylethanolamine

Vidine

Vitamin J

Hypolipidemic Agents

Phase 3

Lipid Regulating Agents

Phase 3

Gastrointestinal Agents

Phase 3

Antimetabolites

Phase 3

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy	Not yet recruiting	NCT03701581	Phase 4	4-Aminopyridine
2	Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities	Completed	NCT02260817	Phase 3	11C-choline Injection
3	A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial	Completed	NCT01470677	Phase 3	Tachosil fibrin patch
4	A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.	Completed	NCT00432107	Phase 2	APO866
5	A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma	Completed	NCT00431912	Phase 2	APO866

Search NIH Clinical Center for Prostate Cancer, Hereditary, 4

Sources

Genetic Tests for Prostate Cancer, Hereditary, 4

Sources

Anatomical Context for Prostate Cancer, Hereditary, 4

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 4:

⁴⁰

Prostate, T Cells, Lung, Breast, Testes

Sources

Publications for Prostate Cancer, Hereditary, 4

Articles related to Prostate Cancer, Hereditary, 4:

(show top 50) (show all 53)

#	Title	Authors	PMID	Year
1	Multiple newly identified loci associated with prostate cancer susceptibility. ⁵⁶	Eeles RA...Easton DF	18264097	2008
2	Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. ⁵⁶	Friedrichsen DM...Xu J	14769943	2004
3	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. ⁶¹	Shore N...Epstein JI	32088746	2020
4	The Role of Stabilization-Free Microsurgical Decompression in the Surgical Treatment of Spinal Metastases. ⁶¹	Muller M...Bostelmann R	31562975	2020
5	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. ⁶¹	Saad M...Ong TA	31077523	2019
6	Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. ⁶¹	Juptner M...Lutzen U	31140181	2019
7	Characterization of the Recommendations in the Choosing Wisely Initiative. ⁶¹	Corrigan K...Kamal A	30345804	2019
8	Prostate cancer detection using quantitative T2 and T2 -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillance. ⁶¹	Giganti F...Kirkham A	29135073	2018
9	Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN-/-/p53-/- Prostate Cancer Cells In Vitro and Ex Vivo. ⁶¹	Pan H...Lin HS	28578487	2018
10	The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy. ⁶¹	Nafie S...Khan M	28299763	2017
11	Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA. ⁶¹	Zhao J...Lu J	28039477	2017
12	Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD. ⁶¹	Zhang J...Chen X	27493267	2017
13	Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. ⁶¹	Shetty D...Do V	27556788	2016
14	Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. ⁶¹	Riola-Parada C...Carreras-Delgado JL	27424217	2016
15	[Mechanisms of castration resistance: Intratumoral hypoxia stimulates the androgen receptor expression]. ⁶¹	Lunardi P...Malavaud B	26896427	2016
16	Lung Cancer and Multiple Neoplasms: A Retrospective Analysis. ⁶¹	Romaszko A...Luks J	26987325	2016
17	Prostate cancer: 4 big questions. ⁶¹	Hodson R	26672789	2015
18	[On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Osteoporosis associated with sex hormone depletion treatment]. ⁶¹	Takahashi S	26320536	2015
19	Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. ⁶¹	Zhu Y...Xie L	25351792	2015
20	The epidemiology of cancer in Angola-results from the cancer registry of the national oncology centre of Luanda, Angola. ⁶¹	Armando A...Miguel F	25729423	2015
21	Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. ⁶¹	Schwingshackl L...Hoffmann G	24599882	2014
22	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. ⁶¹	Lane JA...ProtecT study group	25163905	2014
23	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. ⁶¹	Reis BS...Gnjatic S	24081977	2013
24	Genetic testing in the European Union: does economic evaluation matter? ⁶¹	Antonanzas F...Pinillos M	21598012	2012
25	Stomach metastasis in a patient with prostate cancer 4 years after the initial diagnosis: a case report and a literature review. ⁶¹	Bilici A...Selcukbiricik F	23243531	2012
26	Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature. ⁶¹	Demirci I...Jan?en H	22269186	2012
27	Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. ⁶¹	Medical Advisory Secretariat	23074405	2010
28	Effects of interval between diagnosis and time of survey upon preferred information format for prostate cancer patients. ⁶¹	Sharpley CF...Christie DR	19527371	2009
29	Defining increased future risk for prostate cancer: evidence from a population based screening cohort. ⁶¹	Schroder FH...Fleshner N	19012915	2009
30	[Antioxidant power and cellular damage in prostate cancer]. ⁶¹	Lopez Laur JD...Ortiz A	18709810	2008
31	What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? ⁶¹	Monahan PO...Koch M	17091363	2007
32	Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. ⁶¹	Montgomery EA...Epstein JI	17122505	2006
33	Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. ⁶¹	Parwani AV...Epstein JI	17001156	2006
34	Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. ⁶¹	Clark JA...Talcott JA	16983114	2006
35	Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. ⁶¹	Kobayashi N...Aronson WJ	16899616	2006
36	Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. ⁶¹	Kelavkar UP...McHugh K	16611404	2006
37	Therapeutic targeting of prostate cancer. ⁶¹	Cress AE...Mohla S	15539935	2004
38	Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. ⁶¹	Ngo TH...Aronson WJ	14973081	2004
39	Ethnic differences in quality of life among early breast and prostate cancer survivors. ⁶¹	Gotay CC...Pagano I	11921326	2002
40	Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. ⁶¹	Yamazaki H...Inoue T	11836608	2002
41	[Ultrasound-guided biopsy: screening of prostate cancer with a single set of 14 systematic biopsies]. ⁶¹	Perdona S...D'Armiento M	11221051	2000
42	[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]. ⁶¹	Okubo Y...Ito T	10086262	1999
43	Prostate cancer: 4. Screening. ⁶¹	Meyer F...Fradet Y	9834724	1998
44	Insulin-like growth factors and prostate cancer. ⁶¹	Pollak M...Zhang JC	10453282	1998
45	[Study on the quality of life in patients with prostate cancer]. ⁶¹	Du SF...Zhang HJ	9812508	1997
46	Cancer mortality among pulp and paper workers in Poland. A cohort study. ⁶¹	Szadkowska-Stanczyk I...Szymczak W	9187043	1997
47	Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. ⁶¹	Carter HB...Epstein JI	9436285	1997
48	Combined finasteride and flutamide therapy in men with advanced prostate cancer. ⁶¹	Ornstein DK...Andriole GL	8973674	1996
49	[Screening of cancer of the prostate: study in a Spanish population]. ⁶¹	Herrero Payo JA...Berenguer Sanchez A	8929102	1996
50	Update on urology--prostate cancer. 4--Treatment of local disease. ⁶¹	Bowsher WG	8631420	1995

Sources

Genes for Prostate Cancer, Hereditary, 4

Genes related to Prostate Cancer, Hereditary, 4 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HPC4	Prostate Cancer, Hereditary, 4	Genetic Locus	58.21	Susceptibility factor ⁵⁶ GeneCards inferred via : Gene name (show sections)

Sources

Variations for Prostate Cancer, Hereditary, 4

Sources

Expression for Prostate Cancer, Hereditary, 4

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 4.

Sources

Pathways for Prostate Cancer, Hereditary, 4

Sources

GO Terms for Prostate Cancer, Hereditary, 4

Sources

Sources for Prostate Cancer, Hereditary, 4

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Prostate Cancer, Hereditary, 4 (HPC4)

Aliases & Classifications for Prostate Cancer, Hereditary, 4

MalaCards integrated aliases for Prostate Cancer, Hereditary, 4:

Classifications:

External Ids:

Summaries for Prostate Cancer, Hereditary, 4

Related Diseases for Prostate Cancer, Hereditary, 4

Diseases in the Prostate Cancer family:

Diseases related to Prostate Cancer, Hereditary, 4 via text searches within MalaCards or GeneCards Suite gene sharing:

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 4

Clinical features from OMIM:

Drugs & Therapeutics for Prostate Cancer, Hereditary, 4

Drugs for Prostate Cancer, Hereditary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Prostate Cancer, Hereditary, 4

Anatomical Context for Prostate Cancer, Hereditary, 4

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 4:

Publications for Prostate Cancer, Hereditary, 4

Articles related to Prostate Cancer, Hereditary, 4:

Genes for Prostate Cancer, Hereditary, 4

Genes related to Prostate Cancer, Hereditary, 4 (1 elite genes):

Variations for Prostate Cancer, Hereditary, 4

Expression for Prostate Cancer, Hereditary, 4

Pathways for Prostate Cancer, Hereditary, 4

GO Terms for Prostate Cancer, Hereditary, 4

Sources for Prostate Cancer, Hereditary, 4